Health Canada approves new acne treatment for patients 12 and older

Health Canada has approved a new topical gel treatment called CABTREO, which combines clindamycin phosphate, adapalene, and benzoyl peroxide, for patients aged 12 and older. This treatment is designed to address acne vulgaris, a prevalent skin condition that affects many individuals, particularly teenagers. The gel is to be applied once daily to the affected areas and will be available in pharmacies across Canada starting in the fourth quarter of 2024. Acne vulgaris is the most common skin issue encountered by healthcare professionals in Canada, often leading to emotional distress and potential scarring. Approximately 25% of teenagers continue to experience acne into their mid-twenties, highlighting the need for effective treatments. The introduction of CABTREO is seen as a hopeful development for those suffering from this condition. Clinical studies for CABTREO have shown positive results, meeting all primary efficacy endpoints, including reductions in both inflammatory and non-inflammatory lesions. However, users may experience mild to moderate side effects, such as skin irritation. The treatment is not suitable for individuals with certain medical histories or for pregnant women. The approval of CABTREO is significant for the Acne and Rosacea Society of Canada, as it provides a new option for patients seeking relief from acne. The availability of effective treatments is crucial for improving the emotional and social well-being of those affected by this common skin condition.